Health Ministry Issues Advisory on Stem Cell Therapy; Mandates Clinical Trial Route for Autism Spectrum Disorder

The Union Ministry of Health and Family Welfare has issued an advisory to all States and Union Territories directing strict enforcement of existing regulations governing stem cell treatments, underscoring that stem cell therapy can only be administered as standard clinical care for indications explicitly approved by the Central Government.

The directive follows the Supreme Court judgment dated January 30, 2026, in Yash Charitable Trust & Ors. v. Union of India & Ors., reiterating that unproven regenerative interventions offered commercially or as routine care violate statutory norms.

Key Highlights of the Advisory

Approved Indications Only: Stem cell therapy is legally restricted to specific medical indications approved by the Ministry of Health and Family Welfare. Administering it as routine clinical practice outside this framework is unauthorized.
Strict Limitations on Autism (ASD): The therapeutic use of any type of stem cells for Autism Spectrum Disorder remains confined strictly to duly authorized clinical trials. It cannot be sold, marketed, or provided as routine, standard, or commercial therapy.
Adherence to National Guidelines: All permitted research and clinical trials must strictly follow the National Guidelines for Stem Cell Research, 2017, jointly formulated by the Indian Council of Medical Research (ICMR) and the Department of Biotechnology (DBT).
Enforcement & Disciplinary Action: Violations will be treated as professional misconduct under Regulation 7.22 of the Indian Medical Council (IMC) Regulations, 2002, alongside penal provisions and cancellation of clinic registrations under Sections 32 and 40 of the Clinical Establishments (Registration and Regulation) Act, 2010.

Regulatory Alignment: NMC Directive

The Health Ministry’s advisory aligns with instructions previously issued by the National Medical Commission (NMC) on September 5, 2026:

The NMC instructed all State Medical Councils to treat unauthorized administration, prescription, promotion, or advertising of unapproved stem cell procedures as actionable medical misconduct.
State Medical Councils have been directed to process complaints against registered medical practitioners and impose appropriate disciplinary penalties where violations are established through due inquiry.

Enforcement Framework for States

Regulatory Pillar	Action Mandate
State & District Health Authorities	Disseminate the Supreme Court’s directions across all government and private healthcare facilities.
Clinical Establishments Act, 2010	Inspect facilities; enforce statutory penalties or license revocation under Sections 32 and 40 for unauthorized commercial offerings.
Research Protocols	Ensure any investigational stem cell intervention holds valid ethics committee clearance and DCGI/CDSCO clinical trial approvals under ICMR-DBT 2017 standards.